Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Salarius Pharmaceuticals ( (SLRX) ) has issued an announcement.
On December 19, 2025, Salarius Pharmaceuticals convened its 2025 annual meeting of stockholders but was forced to adjourn without conducting business after failing to reach the required 34% quorum, with only about 30% of eligible common shares represented in person or by proxy. The company set December 31, 2025, as the date to reconvene the virtual annual meeting, keeping the October 24, 2025 record date and the existing slate of proposals unchanged, and emphasized the need for additional shareholder participation by encouraging investors of record to submit or maintain their proxies so that key corporate matters can proceed, a step that underscores governance and voting-engagement challenges at the small-cap drug developer.
Spark’s Take on SLRX Stock
According to Spark, TipRanks’ AI Analyst, SLRX is a Underperform.
Salarius Pharmaceuticals exhibits significant financial instability, characterized by declining revenues and persistent losses, which severely impacts its stock score. Technically, the stock is on a bearish trend, trading below major moving averages, with negative momentum indicators. The valuation is further weakened by a negative P/E ratio and absence of dividend, making it unattractive to value or income investors. Overall, the stock is highly risky and requires cautious consideration.
To see Spark’s full report on SLRX stock, click here.
More about Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies, with a portfolio led by seclidemstat, which is being evaluated in an investigator-initiated Phase 1/2 study at MD Anderson Cancer Center for myelodysplastic syndrome and chronic myelomonocytic leukemia in patients with limited treatment options. Its second asset, SP-3164, is an IND-stage oral small-molecule protein degrader, while its subsidiary Decoy Therapeutics Inc. is a preclinical-stage biotechnology firm using machine learning, AI and high-speed synthesis to design peptide-conjugate drug candidates targeting respiratory viruses and gastrointestinal cancers, backed by institutional investors and strategic life sciences and technology programs.
Average Trading Volume: 1,806,290
Technical Sentiment Signal: Sell
Current Market Cap: $3.83M
See more data about SLRX stock on TipRanks’ Stock Analysis page.